Trans-Hit Bio and Q&T Research enter into an Exclusive Strategic Business Partnership

LAVAL, Quebec--(BUSINESS WIRE)-- Trans-Hit Bio (THB) is pleased to announce today a strategic partnership with Q&T Research to facilitate access by the biopharma community to large quantities of blood collected by plasmapheresis from healthy donors and ambulatory patients that can be used to prepare the large volumes of PBMC. For the vaccine industry, this partnership also promotes access to large volumes of human blood complement.

Q&T Research brings a dedicated research center to THB’s clients. Its excellence in subject recruitment, consistently meeting and surpassing study recruitment goals, enhances THB’s ability to fulfill its mission of providing the most extensive specimen collection capability through IRB-approved collections, transparency and traceability.

This partnership provides us with a unique competitive advantage. Together, THB and Q&T Research offer unprecedented value for pharmaceutical and diagnostics R&D teams by extending our capability to procure high quality biospecimens such as large volumes of PBMCs or plasma collected by plasmapheresis from heathy donors or even from out-patients from the multiple health clinics working with Q&T,” said Pascal Puchois, Chief Executive Officer, Trans-Hit Bio.

From Pierre Gervais, President and Executive Director of Q&T: “This partnership with Trans-Hit Bio represents a new avenue for access to patients and healthy subjects. Q&T’s expertise with Phase II-III clinical research projects provides a solid foundation of patient access and trust, and this partnership opens new doors to patients interested in contributing to medical and scientific development.”


Back to news